Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 14/20 | 0.63 |
| ▸ | PDCD1 | Q15116 | 12/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25059947 | 0.86 | CD274 (0.47) | CD274PDCD1ADORA1 | |
| SCHEMBL23805188 | 0.81 | CD274 (0.60) | CD274PDCD1NPC1 | |
| SCHEMBL30093825 | 0.81 | CD274 (0.60) | CD274PDCD1NPC1 | |
| SCHEMBL18979829 | 0.80 | CD274 (0.67) | CD274PDCD1ADORA1MAPTALOX15 | |
| SCHEMBL18792069 | 0.80 | CD274 (0.67) | CD274PDCD1ADORA1MAPTALOX15 | |
| SCHEMBL31644196 | 0.80 | CD274 (0.67) | CD274PDCD1ADORA1MAPTALOX15 | |
| SCHEMBL18727806 | 0.80 | CD274 (0.67) | CD274PDCD1ADORA1MAPTALOX15 | |
| SCHEMBL25060039 | 0.80 | CD274 (0.52) | CD274PDCD1MAPTNPC1ALDH1A1 | |
| SCHEMBL25059948 | 0.80 | CD274 (0.59) | CD274PDCD1 | |
| SCHEMBL29894237 | 0.77 | CD274 (0.64) | CD274PDCD1ADORA1MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4137489-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Corporation (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-3504198-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2018044783-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20170362253-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362253-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CD274 88/4885PDCD1 157/4885ADORA1 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.